Main Conference Day 3Wednesday, 16 December 2026 - PT (Pacific Time, GMT-08:00)

This presentation will highlight the potential of multispecific antibodies for the treatment of cancer and immunological diseases. It will highlight how novel multispecific antibody designs enable targeted modulation of disease biology, overcome limitations of conventional antibody therapies, and create new opportunities for improved efficacy and safety. Selected preclinical and translational examples will illustrate the promise of these next-generation therapeutics across diverse disease indications.

Treatment of solid tumors with T cell engagers remains a significant challenge due to tumor heterogeneity, low t cell infiltration and the presence of a suppressive tumor microenvironment. We have engineered a trispecific T cell engager platform leveraging CD28 co-stimulation with an excellent developability profile to provide optimal t cell activation and the potential for a more durable response. Our conditional CD28 co-stimulation platform can be combined with multiple geometries and tumor associated antigens to increase efficacy of T cell engagers in both solid and liquid tumors.

Numab’s proprietary MATCH™ and Fc engineering technologies enable routine generation of differentiated multispecific antibodies with up to six specificities while maintaining IgG-like stability and manufacturability. The platform supports diverse molecular architectures, from compact, tissue-penetrating molecules to long-acting therapeutics optimized for subcutaneous or intravenous administration. We will present key design principles for multispecific antibody engineering addressing unmet needs in inflammatory diseases and oncology.

Antibody engineering provides powerful strategies to address unmet medical needs, exemplified by the development of next generation T cell engagers (TCEs). We describe engineering and biological principles underlying CD8 guided TCEs designed to enhance therapeutic index and reduce the risk of cytokine driven toxicities. By preferentially engaging cytotoxic CD8⁺ T cells while limiting CD4⁺ T cell activation, this approach aims to minimize excessive cytokine production without compromising antitumor activity. Our AZD9793, GPC3 targeted, CD8 guided TCE induces potent hepatocellular carcinoma (HCC) cell killing with markedly reduced CD4⁺ T cell activation. This CD8 bias significantly limits the production of CRS related cytokines compared with a conventional GPC3×CD3 TCE, which activates CD8⁺ and CD4⁺ T cells equivalently.

TIE-ADC is a modular bispecific antibody-drug conjugate platform that co-engages a tumor antigen and an immunosuppressor-cell antigen, delivering a shared payload that independently kills both. Engineered avidity-based binding spares normal immune cells. Across cell lines, xenografts, and humanized PDX models, TIE-ADC drove complete tumor regression along with superior immunomodulation by selectively depleting immunosuppressor cells while enriching effector cells—outperforming an approved ADC and a checkpoint inhibitor.v

As multispecific antibody technologies become increasingly competitive, creating valuable intellectual property requires more than protecting individual molecules. This presentation explores how antibody engineers can identify, generate, and support patentable innovations across molecular design, functionality, manufacturing, and platform technologies. Attendees will gain practical insights into building layered patent portfolios that maximize commercial value, strengthen competitive positioning, and support long-term innovation leadership.